angiotensin-receptor blocker

(redirected from Angiotensin II receptor antagonist)
Also found in: Dictionary, Thesaurus, Medical, Financial, Wikipedia.
Related to Angiotensin II receptor antagonist: ACE inhibitor, calcium channel blocker

angiotensin-receptor blocker:

see under ACE inhibitorACE inhibitor
or angiotensin-converting enzyme inhibitor
, drug used to reduce elevated blood pressure (see hypertension), to treat congestive heart failure, and to alleviate strain on hearts damaged as a result of a heart attack (see infarction).
..... Click the link for more information.
.
References in periodicals archive ?
Rarely (probably less often than once in every thousand pregnancies), no alternative to an angiotensin II receptor antagonist will be found.
ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.
Estimated percentage of patients prescribed the following angiotensin II receptor antagonists, for the treatment of Hypertension: losartan (e.
TABLE 48 WORLDWIDE MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS, 2009 (%) 71
The key classes of mechanism of action include dietary supplements, enzyme inhibitors, PPAR (peroxisome proliferator-activated receptor) gamma selective agonists, combination therapies, cholesterol Inhibitors, CB-1 cannabinoid receptor antagonists, angiotensin II receptor antagonists, lipid peroxidation inhibitors, glutathione enhancers and immunologic drugs.
Additionally, agents from drug classes that are typically used in first-, second-, and third-line therapy -- such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRAs), calcium-channel blockers (CCBs), and diuretics -- will all be subject to generic competition.
According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Past and Future Shifts in Tier Placement of Angiotensin II Receptor Antagonists, Single Pill Fixed-Dose Combinations and Novel Agents, step therapy restrictions are becoming more common in commercial health plans across all classes of antihypertensives, suggesting fixed dosed combination agents and novel antihypertensives will face less access on Tier 2 on commercial health plans.
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARBs) have been developed to block this system "down stream" and have shown clinical efficacy in patients with hypertension and other cardiovascular diseases.
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARBs) have been developed to block this system "downstream" and have shown clinical efficacy in patients with hypertension, chronic renal failure, congestive heart failure and other cardiovascular diseases.

Full browser ?